Awarded by ATS at Society for Neuroscience (SFN) Washington, D.C. • November 12-16, 2005 Be sure to check out the cover article contributed by Dr. Lai in our Targeting Trends newsletter (First Quarter, 2006). 394.17 PAIN FACILITATORY CELLS IN THE ROSTRAL VENTROMEDIAL MEDULLA COEXPRESS OPIOID-µ RECEPTORS AND CHOLECYSTOKININ TYPE 2 RECEPTORSW.Zhang*; S.E.Gardell; Y.Xie; M.Luo; N.E.Rance; […]
SFN Poster of the Year 2005 Read More »
New Fluorescent Antibody: Cy3-labeled Anti-murine NGFr (Cat. #AB-N01APFL3) Advanced Targeting Systems introduces a new help in immunostaining: The antibody to mouse nerve growth factor receptor (NGFr, low affinity neurotrophin receptor, p75) conjugated to Cy3. The antibody is our widely-used rabbit polyclonal that has been affinity purified (Cat. #AB-N01AP). As can be seen in the figure
Targeting Tools: Cy3-labeled Anti-murine NGFR Read More »
Contributed by Kevin Pang and Heidi Smith, Bowling Green State University, Dept Psychology, Bowling Green, Ohio Hypocretin (or orexin) neurons are located in the hypothalamus and have been implicated in various functions including sleep, arousal and feeding. One area receiving dense hypocretin projections and expressing hypocretin-2 receptors (H-2r) is the medial septum (MS), an area
Cover Article: Effects of Intraseptal Orexin-Saporin on Spatial Memory Read More »
Advanced Targeting Systems announces three new antibodies to G protein-coupled receptors that will be quite helpful for a number of researchers studying somatostatin and substance P. For somatostatin study, we already market excellent rabbit polyclonals to somatostatin-14 (Cat. #AB-04) and somatostatin-28 (Cat. #AB-05). We now announce a new mouse monoclonal antibody to somatostatin receptor 1
Targeting Tools: SSTr1, SSTr5, NK-1r Read More »
One of the most important features of the Advanced Targeting Systems product line is the availability of control toxins that allow the researcher to fully evaluate results of the treatment of cells or animals with targeted toxins. For instance, anti-DBH-SAP is targeted with a mouse monoclonal antibody. Its control partner is mouse IgG-SAP, that is,
Targeting Tools: Control Immunotoxins Read More »
As most of you know, SP-SAP is a potential therapeutic that ATS is developing for use in the elimination of chronic pain. For the past seven years, preclinical studies have been carried out in the rat, safety and dosing studies completed in the dog and the first of two toxicology studies has begun in the
SP-SAP: How It’s Different From Substance P Antagonists Read More »
Contributed by Lesley E. Northrop, Nicole Cameron and Mary Erskine, Department of Biology, Boston University The posterodorsal medial amygdala (MePD) is involved in processing the information from genito- sensory stimuli which is needed for mating-induced pseudopregnancy. The amygdala complex is known to be involved in memory storage and consolidation, processes known to be influenced by
ATS is pleased to present a polyclonal antibody specific for ChAT protein. Choline acetyltransferase (ChAT) catalyzes the synthesis of the neurotransmitter acetylcholine (ACh) from choline and acetyl-CoA in cholinergic neurons. ChAT serves as a specific marker for cholinergic neurons in both the peripheral and central nervous systems. Dysfunction of cholinergic neurons underlies aspects of clinical
Targeting Tools: Anti-ChAT Read More »
Toxicology studies with the potential chronic pain therapeutic, SP-SAP (Substance P-Saporin) are continuing successfully. The second study will be initiated in a few months and ATS is diligently pursuing a pharmaceutical partner that can quickly bring the drug to clinical trials in humans. With the recent news of the undesirable side effects of such pain
ATS Seeks Strategic Partner for Chronic Pain Drug Read More »